Release of monocyte migration signals by breast cancer cell lines after ablative and fractionated γ-irradiation

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Hennel, Roman ^a   Brix, Nikko ^a   Seidl, Karin ^a   Ernst, Anne ^a   Scheithauer, Heike ^a   Belka, Claus ^a   Lauber, Kirsten ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Ablative radiotherapy; Anti tumor immunity; Chemokinesis; Chemotaxis; Dying cell clearance; Fractionated radiotherapy; Immunogenic cell death; Monocyte migration; Nucleotides

Indexed keywords

APYRASE; CD39 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; HORMONE RECEPTOR; MIGRATION STIMULATING FACTOR; NUCLEOTIDE; PROTEIN P53; LEUKOCYTE ANTIGEN; TP53 PROTEIN, HUMAN;

ABLATIVE RADIOTHERAPY; ADAPTIVE IMMUNITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL DEATH; CELL MIGRATION; CHEMOKINESIS; CHEMOTAXIS; CONTROLLED STUDY; FLOW CYTOMETRY; GAMMA IRRADIATION; HUMAN; HUMAN CELL; MONOCYTE; PROTEIN EXPRESSION; RADIATION DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; SIGNAL TRANSDUCTION; SUPERNATANT; TUMOR IMMUNOLOGY; UPREGULATION; WILD TYPE; BREAST NEOPLASMS; CELL MOTION; CELL PROLIFERATION; CELL SEPARATION; CYTOLOGY; FEMALE; GAMMA RADIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NECROSIS; NUCLEOTIDE SEQUENCE; RADIATION RESPONSE; TUMOR CELL LINE; X RAY;

ANTIGENS, CD; APOPTOSIS; APYRASE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SEPARATION; DNA MUTATIONAL ANALYSIS; FEMALE; FLOW CYTOMETRY; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MONOCYTES; MUTATION; NECROSIS; NUCLEOTIDES; TUMOR SUPPRESSOR PROTEIN P53; X-RAYS;

EID: 84899150225     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-85     Document Type: Article

References (58)

1. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011, 378(9804):1707-1716. 3254252, 22019144.
2. Van Limbergen E, Weltens C. New trends in radiotherapy for breast cancer. Curr Opin Oncol 2006, 18(6):555-562. 10.1097/01.cco.0000245327.42281.9f, 16988575.
3. Budach W. Radiotherapy in patients with metastatic breast cancer. Eur J Cancer 2011, 47(Suppl 3):S23-S27.
4. Budach W, Kammers K, Boelke E, Matuschek C. Adjuvant radiotherapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials. Radiat Oncol 2013, 8(1):267. 10.1186/1748-717X-8-267, 3842771, 24225206.
5. Orth M, Lauber K, Niyazi M, Friedl AA, Li M, Maihofer C, Schuttrumpf L, Ernst A, Niemoller OM, Belka C. Current concepts in clinical radiation oncology. Radiat Environ Biophys 2014, 53(1):1-29. 10.1007/s00411-013-0497-2, 3935099, 24141602.
6. Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 2010, 28(4):639-648. 10.1002/stem.318, 2940232, 20135685.
7. Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008, 9(4):331-341. 2323709, 18356109.
8. Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008, 371(9618):1098-1107. 2277488, 18355913.
9. Vaidya JS, Tobias JS, Baum M, Keshtgar M, Joseph D, Wenz F, Houghton J, Saunders C, Corica T, D'Souza D, Sainsbury R, Massarut S, Taylor I, Hilaris B. Intraoperative radiotherapy for breast cancer. Lancet Oncol 2004, 5(3):165-173. 10.1016/S1470-2045(04)01412-3, 15003199.
10. Tuschy B, Berlit S, Romero S, Sperk E, Wenz F, Kehl S, Sutterlin M. Clinical aspects of intraoperative radiotherapy in early breast cancer: short-term complications after IORT in women treated with low energy x-rays. Radiat Oncol 2013, 8:95. 10.1186/1748-717X-8-95, 3643839, 23607703.
11. Welzel G, Boch A, Sperk E, Hofmann F, Kraus-Tiefenbacher U, Gerhardt A, Suetterlin M, Wenz F. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiat Oncol 2013, 8(1):9. 10.1186/1748-717X-8-9, 3896671, 23294485.
12. Frey B, Rubner Y, Kulzer L, Werthmoller N, Weiss EM, Fietkau R, Gaipl US. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 2014, 63(1):29-36. 10.1007/s00262-013-1474-y, 24052136.
13. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005, 174(12):7516-7523.
14. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008, 180(5):3132-3139.
15. Lee Y, Auh SL, Wang Y, Burnette B, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114(3):589-595. 10.1182/blood-2009-02-206870, 2713472, 19349616.
16. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 2011, 71(7):2488-2496. 10.1158/0008-5472.CAN-10-2820, 3070872, 21300764.
17. Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, Schwendener R, Pruschy M, Knuth A, van den Broek M. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J Immunol 2012, 189(2):558-566. 10.4049/jimmunol.1200563, 22685313.
18. Lauber K, Ernst A, Orth M, Herrmann M, Belka C. Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol 2012, 2:116. 3438527, 22973558.
19. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13(9):1050-1059. 10.1038/nm1622, 17704786.
20. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, Martins I, Schlemmer F, Michaud M, Kepp O, Sukkurwala AQ, Menger L, Vacchelli E, Droin N, Galluzzi L, Krzysiek R, Gordon S, Taylor PR, Van Endert P, Solary E, Smyth MJ, Zitvogel L, Kroemer G. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013, 38(4):729-741. 10.1016/j.immuni.2013.03.003, 23562161.
21. Lauber K, Keppeler H, Munoz LE, Koppe U, Schroder K, Yamaguchi H, Kronke G, Uderhardt S, Wesselborg S, Belka C, Nagata S, Herrmann M. Milk fat globule-EGF factor 8 mediates the enhancement of apoptotic cell clearance by glucocorticoids. Cell Death Differ 2013, 20(9):1230-1240. 10.1038/cdd.2013.82, 23832117.
22. Blume KE, Soeroes S, Keppeler H, Stevanovic S, Kretschmer D, Rautenberg M, Wesselborg S, Lauber K. Cleavage of annexin A1 by ADAM10 during secondary necrosis generates a monocytic " find-me" signal. J Immunol 2012, 188(1):135-145. 10.4049/jimmunol.1004073, 22116825.
23. Peter C, Waibel M, Keppeler H, Lehmann R, Xu G, Halama A, Adamski J, Schulze-Osthoff K, Wesselborg S, Lauber K. Release of lysophospholipid 'find-me' signals during apoptosis requires the ATP-binding cassette transporter A1. Autoimmunity 2012, 45(8):568-573. 10.3109/08916934.2012.719947, 22913458.
24. Rosenwald M, Koppe U, Keppeler H, Sauer G, Hennel R, Ernst A, Blume KE, Peter C, Herrmann M, Belka C, Schulze-Osthoff K, Wesselborg S, Lauber K. Serum-derived plasminogen is activated by apoptotic cells and promotes their phagocytic clearance. J Immunol 2012, 189(12):5722-5728. 10.4049/jimmunol.1200922, 23150713.
25. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009, 4(12):1798-1806. 10.1038/nprot.2009.191, 20010931.
26. Wagner BJ, Lindau D, Ripper D, Stierhof YD, Glatzle J, Witte M, Beck H, Keppeler H, Lauber K, Rammensee HG, Konigsrainer A. Phagocytosis of dying tumor cells by human peritoneal mesothelial cells. J Cell Sci 2011, 124(Pt 10):1644-1654.
27. Harre U, Keppeler H, Ipseiz N, Derer A, Poller K, Aigner M, Schett G, Herrmann M, Lauber K. Moonlighting osteoclasts as undertakers of apoptotic cells. Autoimmunity 2012, 48(8):612-619.
28. Lauber K, Munoz LE, Berens C, Jendrossek V, Belka C, Herrmann M. Apoptosis induction and tumor cell repopulation: the yin and yang of radiotherapy. Radiat Oncol 2011, 6:176. 10.1186/1748-717X-6-176, 3264523, 22182804.
29. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009, 4(7):e6146. 10.1371/journal.pone.0006146, 2702084, 19582160.
30. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006, 13(2):293-325. 10.1677/erc.1.01172, 16728565.
31. Fei P, El-Deiry WS. P53 and radiation responses. Oncogene 2003, 22(37):5774-5783. 10.1038/sj.onc.1206677, 12947385.
32. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80(2):293-299. 10.1016/0092-8674(95)90412-3, 7834749.
33. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001, 7(3):683-694. 10.1016/S1097-2765(01)00214-3, 11463392.
34. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288(5468):1053-1058. 10.1126/science.288.5468.1053, 10807576.
35. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003, 11(3):577-590. 10.1016/S1097-2765(03)00050-9, 12667443.
36. Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. Oncogene 2013, 32(43):5129-5143. 10.1038/onc.2012.640, 23416979.
37. Jones KR, Elmore LW, Jackson-Cook C, Demasters G, Povirk LF, Holt SE, Gewirtz DA. p53-Dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol 2005, 81(6):445-458. 10.1080/09553000500168549, 16308915.
38. Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE, Krimpenfort P, Depinho RA, Bennett DC, Sviderskaya EV, Merlino G. ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A 2007, 104(26):10968-10973. 10.1073/pnas.0611638104, 1904138, 17576930.
39. Burnette B, Fu YX, Weichselbaum RR. The confluence of radiotherapy and immunotherapy. Front Oncol 2012, 2:143. 3472545, 23087904.
40. Berens C, Lauber K, Herrmann M. Autoimmunity vs. cancer: predator vs. alien?. Autoimmunity 2013, 46(5):287-293. 10.3109/08916934.2013.787687, 23706137.
41. Peter C, Wesselborg S, Herrmann M, Lauber K. Dangerous attraction: phagocyte recruitment and danger signals of apoptotic and necrotic cells. Apoptosis 2010, 15(9):1007-1028. 10.1007/s10495-010-0472-1, 20157780.
42. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Genin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, Andre F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G, Zitvogel L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009, 15(10):1170-1178. 10.1038/nm.2028, 19767732.
43. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, Lysiak JJ, Harden TK, Leitinger N, Ravichandran KS. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009, 461(7261):282-286. 10.1038/nature08296, 2851546, 19741708.
44. Isfort K, Ebert F, Bornhorst J, Sargin S, Kardakaris R, Pasparakis M, Bahler M, Schwerdtle T, Schwab A, Hanley PJ. Real-time imaging reveals that P2Y2 and P2Y12 receptor agonists are not chemoattractants and macrophage chemotaxis to complement C5a is phosphatidylinositol 3-kinase (PI3K)- and p38 mitogen-activated protein kinase (MAPK)-independent. J Biol Chem 2011, 286(52):44776-44787. 10.1074/jbc.M111.289793, 3247992, 22057273.
45. Kronlage M, Song J, Sorokin L, Isfort K, Schwerdtle T, Leipziger J, Robaye B, Conley PB, Kim HC, Sargin S, Schon P, Schwab A, Hanley PJ. Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. Sci Signal 2010, 3(132):ra55.
46. Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, Lazarowski ER, Armstrong AJ, Penuela S, Laird DW, Salvesen GS, Isakson BE, Bayliss DA, Ravichandran KS. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 2010, 467(7317):863-867. 10.1038/nature09413, 3006164, 20944749.
47. Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013, 19(6):355-367. 10.1016/j.molmed.2013.03.005, 23601906.
48. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 2011, 187(2):676-683. 10.4049/jimmunol.1003884, 21677139.
49. Berger CE, Qian Y, Liu G, Chen H, Chen X. p53, a target of estrogen receptor (ER) alpha, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells. J Biol Chem 2012, 287(36):30117-30127. 10.1074/jbc.M112.367326, 3436267, 22787161.
50. Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, Saceda M. Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol 2004, 180(3):497-504. 10.1677/joe.0.1800497, 15012604.
51. Menendez D, Inga A, Resnick MA. Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences. Proc Natl Acad Sci U S A 2010, 107(4):1500-1505. 10.1073/pnas.0909129107, 2824383, 20080630.
52. Lion M, Bisio A, Tebaldi T, De Sanctis V, Menendez D, Resnick MA, Ciribilli Y, Inga A. Interaction between p53 and estradiol pathways in transcriptional responses to chemotherapeutics. Cell Cycle 2013, 12(8):1211-1224. 10.4161/cc.24309, 23518503.
53. Hallahan DE, Dunphy E, Virudachalam S, Sukhatme VP, Kufe DW, Weichselbaum RR. C-jun and Egr-1 participate in DNA synthesis and cell survival in response to ionizing radiation exposure. J Biol Chem 1995, 270(51):30303-30309. 10.1074/jbc.270.51.30303, 8530452.
54. Lu S, Becker KA, Hagen MJ, Yan H, Roberts AL, Mathews LA, Schneider SS, Siegelmann HT, MacBeth KJ, Tirrell SM, Blanchard JL, Jerry DJ. Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity. Endocrinology 2008, 149(10):4809-4820. 10.1210/en.2008-0035, 2582927, 18556351.
55. Liu J, Grogan L, Nau MM, Allegra CJ, Chu E, Wright JJ. Physical interaction between p53 and primary response gene Egr-1. Int J Oncol 2001, 18(4):863-870.
56. Stark K, Eckart A, Haidari S, Tirniceriu A, Lorenz M, von Bruhl ML, Gartner F, Khandoga AG, Legate KR, Pless R, Hepper I, Lauber K, Walzog B, Massberg S. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and 'instruct' them with pattern-recognition and motility programs. Nat Immunol 2013, 14(1):41-51.
57. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CC, Beck PL, Muruve DA, Kubes P. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010, 330(6002):362-366. 10.1126/science.1195491, 20947763.
58. Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, Michaud M, Kepp O, Sukkurwala AQ, Vacchelli E, Galluzzi L, Zitvogel L, Kroemer G. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 2013, 2(6):e24568. 10.4161/onci.24568, 3716753, 23894718.